An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Etrolizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms Cottonwood
- Sponsors Roche
- 01 Sep 2016 Planned End Date changed from 1 Nov 2021 to 1 Nov 2019.
- 01 Sep 2016 Planned primary completion date changed from 1 Nov 2021 to 1 Nov 2019.
- 03 Nov 2014 Planned End Date changed from 1 Apr 2026 to 1 Nov 2021 as reported by ClinicalTrials.gov record.